1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Avivagen Inc.

Avivagen Inc.

VIVXF
Avivagen Inc.US flagOther OTC
0.00
USD
- -
- -
7,769.00Market Cap

Total Valuation

Avivagen Inc. carries a market capitalization of 7,769.00, placing it among publicly traded companies globally. Its enterprise value stands at 18.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7,769.00
Enterprise Value18.55M

Share Statistics

Avivagen Inc. currently has 77.69M shares outstanding.

Shares Outstanding77.69M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 15.84, and the price-to-book ratio stands at -0.91.

PE RatioN/A
PS Ratio15.84
PB Ratio-0.91
P/TBV Ratio-1.22
P/FCF Ratio-15.44
P/OCF Ratio-15.44

Enterprise Valuation

On an enterprise value basis, Avivagen Inc. trades at an EV/EBITDA multiple of 20.32 and an EV/FCF ratio of 16.46. The EV/Sales ratio of 25.94 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.78 provides insight into valuation relative to core operating earnings.

EV / Sales25.94
EV / EBITDA20.32
EV / EBIT21.78
EV / FCF16.46

Financial Position

Avivagen Inc. maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -78.15, indicating conservative leverage, while an interest coverage ratio of 0.49 demonstrates limited ability to service its debt obligations.

Current Ratio0.03
Quick Ratio0.01
Debt / Equity-78.15
Debt / EBITDA7.93
Interest Coverage0.49

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-480.19
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.80

Stock Price Statistics

Avivagen Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Beta (5Y)N/A
52-Week Price Change0.000003%
50-Day Moving Average0.00
200-Day Moving Average0.00
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Avivagen Inc. generated 715,219.00 in revenue and converted that into -4.64M in net income, yielding earnings per share of -0.06. EBITDA reached 913,251.00, while operating income came in at 851,862.00.

Revenue715,219.00
Gross Profit305,385.00
Operating Income851,862.00
Pretax Income-4.64M
Net Income-4.64M
EBITDA913,251.00
EBIT851,862.00
Earnings Per Share (EPS)-0.06

Balance Sheet

Avivagen Inc. holds 17,183.00 in cash and equivalents against 7.24M in total debt, resulting in a net debt position of 7.22M. Total book value stands at -12.51M, with working capital of -8.22M providing operational flexibility.

Cash & Cash Equivalents17,183.00
Total Debt7.24M
Net Debt7.22M
Equity (Book Value)-12.51M
Book Value Per Share-0.16
Working Capital-8.22M

Cash Flow

Avivagen Inc. produced -733,717.00 in operating cash flow over the past twelve months.

Operating Cash Flow-733,717.00
Capital ExpendituresN/A
Free Cash Flow-733,717.00
FCF Per Share-0.01

Margins

Avivagen Inc. operates with a gross margin of 42.70, reflecting its pricing power and cost economics. The operating margin of 119.11 and net profit margin of -648.74 provide insight into operational efficiency.

Gross Margin42.70
Operating Margin119.11
Pretax Margin-648.74
Profit Margin-648.74
EBITDA Margin127.69

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-2.26
FCF Yield-6.48

Stock Splits

Avivagen Inc.'s most recent stock split took place on May 25, 2017 with a 10:1 split ratio.

Last Split Date5/25/2017
Split Ratio10:1

Scores

Avivagen Inc. posts an Altman Z-Score of -266.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-266.18